Kanis, J. A, Hans, D., Cooper, C., Baim, S., Bilezikian, J. P, Binkley, N., Cauley, J. A, Compston, J. E, Dawson-Hughes, B., Fuleihan, G. E, Johansson, H., Leslie, W. D, Lewiecki, E. M, Luckey, M. M, Oden, A., Papapoulos, S., Poiana, C., Rizzoli, R., Wahl, D. A & McCloskey, E. (2011). Interpretation and use of FRAX in clinical practice. Osteoporosis International,22(9), 2395-2411. United Kingdom: Springer Verlag. Retrieved from https://doi.org/10.1007/s00198-011-1713-z
Summary The introduction of the WHO FRAX® algorithms has facilitated the assessment of fracture risk on the basis of fracture probability. Its use in fracture risk prediction has strengths, but also limitations of which the clinician should be aware and are the focus of this review Introduction The International Osteoporosis Foundation (IOF) and the International Society for Clinical Densitometry (ISCD) appointed a joint Task Force to develop resource documents in order to make recommendations on how to improve FRAX and better inform clinicians who use FRAX. The Task Force met in November 2010 for 3 days to discuss these topics which form the focus of this review. Methods This study reviews the resource documents and joint position statements of ISCD and IOF. Results Details on the clinical risk factors currently used in FRAX are provided, and the reasons for the exclusion of others are provided. Recommendations are made for the development of surrogate models where country-specific FRAX models are not available. Conclusions The wish list of clinicians for the modulation of FRAX is large, but in many instances, these wishes cannot presently be fulfilled; however, an explanation and understanding of the reasons may be helpful in translating the information provided by FRAX into clinical practice.
Institute for Health and Ageing
Access may be restricted.